ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th: Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C ., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE:ZTS) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”). Investors have until July 27, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.